How Has The Peptide Therapeutics Market Size Evolved In Recent Years?
The peptide therapeutics market has seen considerable growth due to a variety of factors.
• In recent times, the size of the peptide therapeutics market has seen swift expansion. It is projected to rise from $45.15 billion in 2024 to $49.67 billion in 2025, maintaining a compound annual growth rate (CAGR) of 10.0%.
The growth seen in the historical period can be traced back to factors such as a rise in chronic disease prevalence, enhanced comprehension of molecular biology, and widening utilization in the field of oncology.
What Is the Forecasted Market Size and Growth Rate for The Peptide Therapeutics Market?
The peptide therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• Over the coming years, a surge is expected in the market size for peptide therapeutics, with the estimated value expected to reach approximately $76.64 billion by 2029, boasting a compound annual growth rate (CAGR) of around 11.5%.
Several factors can be attributed to this anticipated growth during the forecasted period, namely the rising demand for personalized healthcare solutions, the increasing usage in immunotherapy, advancements made in peptide delivery platforms, the unveiling of peptide targets in the context of infectious illnesses, and an amplified focus on rare diseases. Noteworthy trends in the upcoming period include the technological enhancements in the process of peptide synthesis, increased investments and funding, a significant focus on the safety of peptide drugs, market growth in developing economies, and the introduction of artificial intelligence (AI).
What Are The Core Factors Supporting Growth In Peptide Therapeutics Market?
The peptide therapeutics market's growth is projected to be driven by the rising occurrence of chronic illnesses. These illnesses, which are typically enduring and often not entirely curable, can occasionally be managed and treated. Factors such as increased tobacco use, poor nutritional habits, physical inactivity, and excessive alcohol consumption have contributed to the surge of chronic diseases. Peptide therapeutics play a critical role in preventing and treating some of these diseases. For instance, the National Library of Medicine, a US agency, projected in January 2023 that by 2050, the population of people aged 50 and older suffering from at least one chronic ailment in the US would grow by 99.5%, amounting to 142.66 million individuals. Consequently, the escalation in chronic disease prevalence is anticipated to fuel the peptide therapeutics market during the projected period.
What Key Areas Define The Segmentation Of The Global Peptide Therapeutics Market?
The peptide therapeutics market covered in this report is segmented –
1) By Type: Generic, Branded
2) By Route of Administration: Parenteral, Mucosal, Oral, Transdermal
3) By Application: Cancer, Cardiovascular Diseases, Central Nervous Systems, Metabolic Disorders, Infections, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders, Acromegaly, Other Applications
Subsegments:
1) By Generic: Generic Peptide Drugs, Biosimilars
2) By Branded: Innovative Peptide Drugs, Patent-Protected Peptides
Pre-Book The Peptide Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Peptide Therapeutics Market?
Prominent firms in the peptide therapeutics market are concentrating on developing innovative solutions like the cell culture process to enhance their competitive position. The cell culture process, which involves growing cells outside their natural environment under regulated conditions and isolating interested cells from living tissue, is one such advancement. For example, Evonik Industries AG, a specialty chemical corporation based in Germany, introduced cQrex KC in June 2023. This next-generation peptide is crafted for biopharma applications and specifically designed for the cell culture process used in the production of biological medications. This innovation not only assists cell culture process developers in optimizing cystine supply but also boosts cell culture productivity. Additionally, cQrex KC plays an instrumental role in the progress of vaccines, viral vectors, and cell therapies.
Who Are the Key Players in the Peptide Therapeutics Market?
Major companies operating in the peptide therapeutics market include:
• Pfizer Inc.
• Jhonson & Jhonson
• Abbvie Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Sanofi SA
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Novo Nordisk AS
• Teva Pharmaceuticals Industries Ltd.
• Bachem Holding AG
• PolyPeptide Laboratories BV
• Arcus Biosciences Inc.
• Pepscan Therapeutics
• Peptech Inc.
• Peptide Logic Inc.
• SELLAS Life Sciences Group
• Ever Neuro Pharma GmbH
• Zealand Pharma AG
• PepGen Inc.
• Pepticom S.A.
• Peptide Technologies Corporation
• SynPeptide Inc.
• Peptimmune Inc.
• Merck & Co Inc.
What Is The Most Dominant Region In The Peptide Therapeutics Market?
North America was the largest region in the peptide therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
